object
safeti
efficaci
proteas
inhibitor
test
cohort
clientown
cat
variou
form
felin
infecti
periton
fip
method
twenti
cat
month
age
mean
month
variou
form
fip
accept
field
trial
fourteen
cat
present
wet
drytowet
fip
six
cat
present
dri
fip
administ
subcutan
everi
h
dose
mgkg
cat
neurolog
sign
exclud
studi
result
nineteen
cat
treat
regain
outward
health
within
week
initi
treatment
howev
diseas
sign
recur
week
primari
treatment
relaps
new
case
ultim
treat
minimum
week
relaps
longer
respons
treatment
occur
cat
within
week
initi
repeat
treatment
sever
neurolog
diseas
occur
cat
fail
treatment
five
cat
recurr
abdomin
lesion
time
write
seven
cat
diseas
remiss
five
kitten
age
month
wet
fip
treat
week
diseas
remiss
stop
treatment
time
write
month
mean
month
sixth
kitten
remiss
week
week
treatment
relaps
respond
second
round
seventh
cat
mesenter
lymph
node
involv
went
remiss
three
relaps
requir
progress
longer
repeat
treatment
month
period
side
effect
treatment
includ
transient
sting
upon
inject
occasion
foci
subcutan
fibrosi
hair
loss
retard
develop
abnorm
erupt
perman
teeth
cat
treat
week
age
conclus
relev
show
promis
treat
cat
certain
present
fip
open
door
target
antivir
drug
therapi
drug
directli
inhibit
viru
replic
becom
mainstay
treatment
chronic
viral
infect
hivaid
hepat
c
viru
hcv
hepat
b
viru
herpesviru
acut
infect
influenza
rna
virus
hcv
possess
ideal
target
viru
inhibit
rnadepend
rna
polymeras
proteas
proteas
particularli
good
target
involv
viru
matur
hiv
product
function
viral
protein
hcv
proteas
inhibitor
also
use
combin
inhibitor
revers
transcript
hivaid
lifelong
therapi
combin
differ
proteas
inhibitor
highli
effect
cure
hcv
infect
peopl
therefor
surpris
viral
proteas
also
attract
target
research
rna
viru
infect
anim
kim
et
al
synthes
peptidyl
compound
target
proteas
evalu
efficaci
felin
coronaviru
fcov
felin
caliciviru
well
import
human
rna
virus
encod
relat
proteas
identifi
seri
compound
show
potent
inhibitori
activ
variou
coronavirus
includ
fcov
wide
margin
safeti
vivo
efficaci
inhibitor
evalu
mice
infect
murin
hepat
viru
murin
coronaviru
found
caus
signific
reduct
viru
titer
patholog
lesion
current
commerci
avail
antivir
drug
coronaviru
infect
peopl
anim
studi
kim
et
al
show
proof
princip
inhibit
lead
suppress
coronaviru
replic
vivo
suggest
inhibitor
may
use
therapeut
agent
import
virus
domest
wild
cat
demonstr
case
subsequ
studi
use
experiment
felin
infecti
periton
fip
viru
fipv
infect
laboratori
cat
although
experiment
fipv
infect
highli
fatal
infect
reach
defin
stage
day
treatment
caus
rapid
diseas
remiss
six
cat
last
month
time
write
remaind
studi
conduct
protocol
approv
institut
anim
care
use
committe
clinic
trial
review
board
veterinari
medic
teach
hospit
clinic
trial
committe
univers
california
davi
protocol
detail
condit
test
novel
proteas
inhibitor
clientown
cat
owner
requir
read
consent
condit
trial
supplementari
materi
present
studi
design
evalu
inhibitor
group
cat
natur
occur
fip
studi
incorpor
placebo
group
note
miller
brodi
lead
ethic
posit
placebocontrol
clinic
trial
whenev
proven
effect
treatment
exist
given
condit
uneth
test
new
treatment
condit
placebo
proven
highli
effect
cure
cat
experiment
induc
fip
prior
studi
effect
treatment
presum
avail
natur
histori
diseas
group
substitut
placebo
control
none
treat
cat
demonstr
last
favor
respons
treatment
receiv
prior
therapi
institut
rule
preclud
use
cat
obtain
shelter
similar
facil
research
even
type
thu
requir
cat
legal
own
adopt
treat
strict
client
consent
supplementari
materi
cat
clinic
appar
neurolog
diseas
also
includ
twenti
cat
variou
region
usa
vari
age
differ
present
form
fip
ultim
enrol
trial
rel
small
group
cat
allow
valuabl
insight
trial
design
owner
interact
complianc
monitor
safeti
efficaci
establish
minim
dosag
regimen
evalu
diseas
relaps
follow
treatment
determin
clinic
form
fip
amen
treatment
inform
hope
assist
addit
test
requir
licens
eventu
commerci
conduct
similar
trial
futur
antivir
drug
fipv
chronic
viral
infect
cat
twenti
cat
owner
ultim
includ
trial
pertin
inform
cat
given
tabl
entir
trial
group
figur
cat
present
studi
vari
degre
pretest
primarycar
veterinarian
test
usual
includ
complet
blood
count
cbc
total
plasma
protein
globulin
g
albumin
g
serum
chemistri
profil
analysi
effus
includ
total
protein
actual
estim
cell
count
type
inflammatori
cell
addit
test
perform
small
proport
cat
includ
fipv
antibodi
titer
abdomin
thorac
ultrasound
biopsi
diseas
tissu
quantit
realtim
pcr
qrtpcr
effus
cat
clinic
sign
indic
neurolog
involv
exclud
trial
base
earlier
unpublish
experiment
studi
one
cat
longterm
survivor
earlier
pharmacokinet
efficaci
trial
recurr
fip
manifest
neurolog
sign
month
appear
success
treatment
acut
infect
cat
fail
respond
repeat
cours
prompt
studi
abil
drug
penetr
brain
level
brain
laboratori
cat
plasma
drug
concentr
diagnosi
fip
confirm
time
entri
studi
base
signal
clinic
histori
examin
prior
laboratori
test
result
physic
examin
repeat
basic
blood
effus
analys
manual
palpat
abdomen
usual
suffici
identifi
ascit
enlarg
mesenter
lymph
node
enlarg
cecum
associ
ileocecalcol
lymph
node
mass
kidney
colon
infiltr
manual
palpat
augment
necessari
ultrasonographi
eye
examin
initi
direct
light
abnorm
retina
precipit
anterior
chamber
back
cornea
aqueou
flare
presenc
ocular
diseas
confirm
question
complet
ophthalmoscop
examin
conduct
ophthalmolog
servic
veterinari
medic
teach
hospit
vmth
uc
davi
presenc
fipv
confirm
qrtpcr
either
abdomin
thorac
effus
taken
time
admiss
time
necropsi
sequenc
fipv
proteas
gene
carri
cat
relaps
therapi
determin
whether
potenti
mutat
confer
drug
resist
occur
diagnosi
drytowet
fip
three
cat
base
diffus
enlarg
colon
histori
loos
stool
blood
mucu
stool
strain
defec
smallcalib
stool
prior
occurr
abdomin
effus
colon
fip
describ
specif
variant
form
noneffus
fip
drytowet
fip
also
suspect
cat
owe
stunt
growth
preced
appear
abdomin
effus
mani
week
treatment
regimen
synthes
highli
pure
form
formul
concentr
mgml
ethanol
polyethylen
glycol
describ
previous
administ
subcutan
sc
effect
dosag
cat
experiment
induc
fip
mgkg
sc
dosag
rais
mgkg
first
cat
fail
respond
lower
dose
mgkg
suggest
earlier
pharmacokinet
studi
clinic
decis
base
one
cat
respons
treatment
monitor
respons
treatment
cat
fip
base
pretest
initi
evalu
time
present
uc
davi
hospit
least
day
immedi
start
treatment
close
evalu
least
twice
daili
rectal
temperatur
puls
respir
appetit
activ
clump
litter
use
allow
daili
evalu
stool
volum
consist
urin
whole
blood
collect
edta
heparin
venepunctur
prior
start
treatment
day
interv
hospit
time
discharg
week
interv
first
month
monthli
greater
interv
thereaft
routin
blood
test
time
point
includ
minimum
hematocrit
total
plasma
protein
icteru
index
total
white
blood
cell
count
differenti
white
blood
cell
percentag
absolut
neutrophil
lymphocyt
monocyt
eosinophil
count
blood
serum
chemistri
valu
taken
period
check
potenti
drug
toxic
sampl
abdomin
effus
obtain
paracentesi
everi
day
obtain
usual
first
day
cat
present
dyspnea
examin
thorac
ultrasonographi
fluid
sampl
obtain
ultrasoundguid
paracentesi
effus
examin
presenc
fibrin
precipit
admixtur
neutrophil
smalllarg
mononuclear
cell
intens
yellow
discolor
viscos
thread
total
protein
content
cell
pellet
periton
thorac
effus
also
examin
qrtpcr
viral
rna
level
previous
describ
cat
discharg
owner
posit
respons
treatment
note
usual
within
day
owner
instruct
either
trial
veterinarian
primarycar
veterinarian
administ
medic
twice
day
subcutan
inject
inject
site
vari
includ
toplin
nape
midback
side
chest
flank
care
taken
avoid
deposit
drug
dermi
sequenti
subcutan
site
owner
encourag
keep
daili
log
rectal
temperatur
activ
appetit
defec
urin
weekli
biweekli
bodi
weight
period
blood
sampl
cbc
serum
chemistri
valu
obtain
owner
person
veterinarian
sent
commerci
veterinari
diagnost
laboratori
abnorm
sign
behavior
note
promptli
report
euthanasia
requir
conduct
either
uc
davi
primarycar
veterinarian
bodi
cat
euthan
primarycar
veterinarian
immedi
refriger
sent
ice
pack
overnight
express
mail
uc
davi
necropsi
owner
request
care
final
disposit
bodi
honor
first
five
cat
trial
treat
initi
week
rapid
improv
health
observ
cat
treatment
stop
despit
favor
initi
respons
diseas
sign
recur
week
week
treatment
end
figur
cat
retreat
rational
progress
extend
primari
secondari
treatment
period
long
fip
remain
respons
see
figur
new
cat
enter
trial
next
treat
week
cat
respond
initi
diseas
sign
reappear
treatment
cat
develop
neurolog
diseas
wherea
cat
recurr
abdomin
lesion
tabl
primari
secondari
treatment
period
extend
week
figur
cat
develop
neurolog
sign
week
primari
treatment
eventu
euthan
diseas
sign
becam
sever
cat
develop
neurolog
diseas
week
start
second
treatment
point
new
cat
admit
trial
earlier
cat
treat
retreat
least
week
benefit
week
treatment
appar
cat
treat
three
time
shorter
period
eventu
relaps
figur
treatment
stop
cat
clinic
laboratori
diseas
sign
week
either
primari
secondari
treatment
determin
minimum
treatment
period
around
week
cat
treat
week
delay
improv
total
protein
white
blood
cell
count
figur
cat
suffer
relaps
pleural
fip
week
later
time
write
receiv
treatment
dramat
progress
improv
health
observ
cat
first
week
time
scale
treatment
clinic
outcom
cat
enter
field
trial
proteas
inhibitor
period
cat
treat
identifi
solid
line
date
last
day
treatment
six
cat
achiev
sustain
clinic
remiss
indic
cat
still
treatment
time
write
remain
cat
succumb
nonneurolog
fip
neurolog
fip
neurofip
primari
secondari
treatment
week
treatment
except
cat
respond
decreas
rectal
temperatur
first
day
treatment
howev
fever
return
health
continu
deterior
next
day
cat
euthan
fever
cat
disappear
within
h
associ
parallel
improv
appetit
activ
growth
weight
gain
abdomin
effus
usual
nondetect
within
week
residu
thorac
effus
remain
initi
therapeut
drainag
larg
gone
day
cat
renal
mass
cat
also
decreas
rapidli
size
nonpalp
week
enlarg
mesenter
lymph
node
somewhat
slower
return
normal
size
palpabl
thicken
colon
associ
ileocecalcol
mass
slowest
resolv
colon
sign
persist
cat
face
treatment
return
otherwis
normal
health
jaundic
frequent
find
younger
cat
effus
fip
slowli
resolv
week
parallel
decreas
hyperbilirubinemia
sign
ocular
diseas
began
clear
within
h
gone
week
regardless
initi
sever
figur
weight
gain
simpl
accur
measur
growth
improv
health
valu
monitor
paramet
typifi
oldest
cat
trial
figur
cat
present
signific
weight
loss
gain
weight
round
treatment
began
lose
weight
shortli
diseas
relaps
regain
ad
weight
treatment
regain
lost
weight
month
treatment
kg
kg
kitten
sustain
remiss
steadili
gain
weight
antivir
treatment
indic
normal
growth
continu
antivir
treatment
figur
one
longterm
survivor
spay
two
castrat
without
complic
diseas
remiss
lymphopenia
common
present
clinic
featur
cat
wet
fip
figur
tend
directli
correl
sever
abdomin
inflamm
indic
viscos
presenc
fibrin
tag
protein
content
cell
count
degre
yellow
color
effus
lymphopenia
improv
treatment
cat
wet
fip
except
help
predict
diseas
relaps
occur
thereaft
figur
lymphopenia
evid
cat
dri
fip
help
paramet
assess
treatment
respons
figur
total
plasma
protein
level
indirect
measur
globulin
concentr
frequent
elev
present
valu
highli
variabl
first
week
often
increas
transient
resorpt
effus
cat
ultim
fail
treatment
tend
higher
total
plasma
protein
concentr
onset
treatment
tend
maintain
higher
level
treatment
cat
success
achiev
sustain
remiss
figur
sequenti
ascit
sampl
collect
cat
first
day
antivir
treatment
test
level
viral
rna
qrtpcr
fipv
level
frequent
low
neg
blood
cat
fip
highest
cell
effus
therefor
cell
ascit
pleural
effus
reliabl
sourc
fipv
rna
cat
time
higher
level
viral
rna
respect
lowest
viru
load
effus
prior
treatment
figur
viral
rna
level
decreas
within
week
compar
pretreat
valu
except
cat
figur
second
highest
viral
rna
level
prior
antivir
treatment
among
cat
effus
sampl
avail
test
figur
failur
viral
rna
level
rapidli
decreas
along
sever
lymphopenia
may
explain
respond
treatment
also
somewhat
slower
drop
viru
level
relaps
twice
antivir
treatment
noteworthi
viral
rna
level
ascit
cell
cat
decreas
fastest
also
among
five
cat
went
sustain
diseas
remiss
whether
properti
individu
fipv
isol
form
sever
host
diseas
determin
treatment
failur
due
recurr
abdomin
fip
occurr
neurolog
diseas
thirteen
cat
trial
ultim
succumb
recurr
diseas
one
cat
fail
show
signific
improv
euthan
week
appear
eye
cat
start
treatment
week
later
b
cat
develop
sever
neurolog
sign
week
start
treatment
start
week
treatment
regimen
figur
wherea
experienc
variabl
period
diseas
remiss
follow
primari
secondari
treatment
last
week
averag
week
figur
one
cat
necropsi
tabl
eight
cat
euthan
sever
neurolog
sign
five
recurr
abdomin
diseas
figur
three
cat
succumb
neurolog
diseas
present
ocular
fip
ocular
involv
detect
secondarili
examin
tabl
earliest
sign
neurolog
diseas
includ
fever
persist
face
continu
treatment
listless
sporad
muscl
twitch
ear
muscl
abnorm
swallow
movement
compuls
stretch
limb
loss
normal
mentat
indic
brief
stare
episod
withdraw
sign
persist
face
treatment
day
week
ultim
progress
incoordin
tonicclon
seizur
appear
rapid
progress
neurolog
sign
apt
occur
discontinu
treatment
treatment
figur
five
cat
recurr
typic
intraabdomin
lesion
absenc
neurolog
sign
treatment
tabl
four
present
ileocec
mass
enlarg
colon
lymph
node
decreas
size
becam
longer
palpabl
follow
primari
treatment
howev
continu
suffer
sever
constip
strain
toothpastelik
stool
sever
colon
obstruct
necessit
colon
resect
reliev
clinic
sign
prevent
eventu
recurr
abdomin
diseas
three
cat
present
sever
ileocecalcol
attempt
treat
neurolog
diseas
increas
drug
dose
treatment
durat
attempt
made
allevi
neurolog
sign
increas
dose
thu
increas
blood
level
amount
drug
pass
across
bloodbrain
barrier
cat
present
effus
fip
initi
treat
mgkg
sc
day
cat
respond
well
fever
return
day
dosag
increas
mgkg
day
fever
disappear
treatment
stop
day
fever
return
day
later
along
vagu
neurolog
sign
consist
muscl
twitch
abnorm
limb
stretch
abnorm
point
indic
fold
reduct
viral
rna
level
measur
prior
treatment
day
viru
rna
level
determin
use
quantit
realtim
pcr
method
betaactin
refer
gene
swallow
motion
cat
immedi
put
back
treatment
dosag
mgkg
sc
condit
improv
shortli
worsen
return
fever
vagu
neurolog
sign
mild
incoordin
dosag
increas
mgkg
sc
day
condit
improv
near
normal
treatment
stop
neurolog
sign
immedi
return
cat
treat
four
addit
day
mgkg
sc
time
neurolog
sign
improv
howev
decis
made
stop
treatment
time
cat
condit
remain
stabl
week
cat
develop
extrem
incoordin
dementia
tonicclon
seizur
euthanasia
perform
necropsi
demonstr
lesion
brain
cat
respond
well
treatment
dosag
mgkg
sc
rectal
temperatur
return
normal
within
h
abdomin
effus
disappear
within
week
cat
appear
normal
second
week
treatment
develop
persist
fever
owner
felt
cat
otherwis
normal
activ
appetit
treatment
continu
dosag
howev
fever
persist
subtl
behavior
sign
note
cat
fail
grow
expect
cat
continu
treatment
week
time
drug
dosag
transient
decreas
twice
ie
mgkg
mgkg
sever
day
fever
increas
activ
decreas
time
mgkg
dosag
reinstitut
cat
continu
show
sign
variabl
fever
vagu
behavior
sign
owner
optimist
cat
appetit
level
activ
cat
treatment
stop
use
drug
purpos
could
justifi
cat
condit
remain
unchang
persist
fever
reclus
behavior
failur
grow
anoth
week
sever
neurolog
sign
consist
incoordin
dementia
seizur
appear
week
cat
euthan
gross
microscop
lesion
limit
brain
emerg
drugresist
viru
consid
cat
relaps
abdomin
lesion
initi
favor
respons
granulomat
coliti
drytowet
abdomin
fip
granulomat
lesion
still
present
abdomen
time
necropsi
gross
microscop
lesion
found
brain
tabl
therefor
diseas
recurr
relat
neurolog
diseas
persist
fipv
antigen
identifi
macrophag
granulomat
lesion
sequenc
comparison
perform
pretreat
effus
omentum
collect
necropsi
day
later
howev
aminoacid
substitut
found
indic
emerg
drugresist
viru
caus
cat
recurr
diseas
sequenc
pretreat
viral
rna
obtain
day
day
day
day
later
time
necropsi
also
compar
differ
observ
time
sequenc
also
remain
unchang
time
present
necropsi
viral
lung
spleen
cat
relaps
twice
month
retreat
asptos
substitut
posit
lystoasp
substitut
posit
compar
viru
pretreat
abdomin
fluid
exact
effect
mutat
proteas
function
current
investig
report
genet
evolut
viral
protein
quasispeci
aris
time
patient
chronic
infect
rna
viru
hcv
may
lead
sporad
amino
acid
chang
seven
cat
treatment
trial
receiv
least
week
continu
treatment
categor
potenti
treatment
success
base
week
diseas
remiss
follow
cessat
treatment
figur
six
kitten
present
acut
effus
diseas
abdomen
chest
month
age
treat
continu
cat
week
tabl
figur
seventh
cat
randombr
castrat
male
present
dri
fip
limit
mesenter
lymph
node
also
achiev
section
greatli
thicken
wall
resect
colon
cat
immunoperoxidas
brown
color
stain
felin
infecti
periton
viru
antigen
seen
macrophag
around
peripheri
granulomat
lesion
viru
persist
colon
occur
presenc
treatment
regress
sign
diseas
eg
effus
periton
longterm
remiss
four
round
treatment
increas
durat
tabl
figur
six
longterm
survivor
abnorm
cbc
hematocrit
total
protein
onset
treatment
complet
normal
blood
valu
time
treatment
stop
howev
cat
still
elev
plasma
protein
level
increas
white
cell
count
week
continu
treatment
anoth
week
plasma
protein
white
cell
count
improv
addit
week
treatment
still
within
normal
paramet
thirteen
week
stop
treatment
cat
develop
typic
fip
effus
chest
fever
chest
fluid
drain
improv
breath
cat
start
second
round
time
write
afebril
activ
eat
normal
week
treatment
treatment
last
week
sign
diseas
reappear
two
side
effect
consequ
observ
treatment
drug
often
caus
sting
inject
subcutan
swell
occur
mani
inject
given
site
rapidli
resolv
deep
local
ulcer
occur
shoulder
blade
one
cat
week
week
treatment
period
howev
evid
dermal
fip
observ
necropsi
like
respons
continu
inject
site
survey
seven
longterm
survivor
demonstr
palpabl
focal
subcutan
thicken
four
peasiz
nodul
shoulder
blade
one
cat
calcifi
radiograph
nodul
along
surround
fibrou
tissu
surgic
remov
three
longterm
survivor
small
focal
area
perman
hair
loss
inject
site
obscur
surround
coat
figur
owner
veterinarian
ask
period
inspect
lesion
chang
charact
check
new
one
consequenti
side
effect
associ
longterm
treatment
involv
juvenil
dentit
normal
format
growth
erupt
perman
teeth
delay
four
kitten
treat
start
month
age
canin
incisor
fourth
premolar
molar
least
affect
wherea
second
third
premolar
affect
figur
adult
teeth
appear
smaller
normal
coupl
delay
erupt
led
either
retent
decidu
canin
failur
decidu
teeth
shed
partial
erupt
abnorm
perman
teeth
lingual
retain
decidu
teeth
anatom
physiolog
defect
observ
longterm
survivor
note
cat
necropsi
bodi
cat
ultim
fail
treatment
submit
necropsi
includ
gross
histolog
examin
immunohistochemistri
diseas
tissu
fipv
antigen
tissu
collect
examin
includ
repres
section
major
adult
dentit
cat
treat
week
start
month
age
retent
upper
left
decidu
canin
upper
second
third
premolar
appear
decidu
small
perman
third
premolar
partial
erupt
lingual
decidu
third
upper
premolar
gingiva
surround
retain
canin
premolar
inflam
adult
canin
also
appear
smaller
normal
perman
right
canin
fourth
upper
premolar
appear
erupt
normal
abdomin
thorac
organ
brain
eye
gross
examin
identifi
three
distinct
present
five
cat
gross
evid
activ
fip
three
lesion
consist
noneffus
fip
four
effus
periton
multiorgan
involv
histolog
five
cat
lack
gross
evid
diseas
demonstr
mostli
mild
mononuclear
infiltr
usual
perivascular
inflamm
eye
liver
intestin
wall
kidney
three
cat
noneffus
fip
mildtosever
inflamm
mani
organ
sever
lesion
occur
eye
mesenter
lymph
node
kidney
lung
three
cat
effus
fip
sever
pyogranulomat
inflamm
multipl
abdomin
organ
includ
omentum
peritoneum
intestin
wall
mesenter
lymph
node
liver
spleen
sever
inflamm
stereotyp
cerebr
fip
present
brain
one
eight
cat
present
necropsi
gross
evid
fip
noneffus
fip
one
cat
without
characterist
brain
lesion
sever
cerebr
edema
contrast
typic
fip
lesion
absent
brain
three
cat
present
necropsi
effus
fip
stereotyp
fip
lesion
brain
character
moderatetosever
chronic
meningoenceph
ventricul
associ
periventricular
parenchym
necrosi
figur
fourth
ventricl
sever
affect
mening
commonli
observ
ventral
cerebellum
brainstem
thick
perivascular
cuff
associ
vascul
frequent
observ
fip
antigen
demonstr
immunoperoxidas
stain
brain
case
stereotyp
cerebr
fip
figur
tissu
cat
necropsi
test
presenc
fipv
rna
qrtpcr
test
posit
thu
establish
persist
viru
cat
fail
treatment
success
treatment
experiment
fipv
infect
prompt
us
investig
whether
could
equal
efficaci
natur
occur
fip
signific
differ
experiment
effus
abdomin
fip
natur
occur
diseas
experiment
diseas
bypass
critic
earli
stage
start
kitten
exposur
innocu
felin
enter
coronaviru
fecv
natur
occur
fip
result
specif
mutant
aris
follow
fecv
infect
fip
occur
presenc
fecv
immun
experiment
fip
contrast
induc
coronaviru
cat
intraperiton
inject
larg
dose
laboratori
catpassag
purifi
fipv
natur
occur
diseas
often
subclin
mani
week
month
outward
sign
diseas
observ
wherea
experiment
diseas
sign
appear
within
week
rapidli
progress
natur
occur
fip
present
varieti
clinic
form
wherea
experiment
infect
almost
alway
effus
abdomin
fip
natur
also
affect
milieu
diseas
enhanc
cofactor
experiment
diseas
occur
cat
free
extran
influenc
differ
may
explain
small
proport
cat
natur
expos
fipv
develop
diseas
wherea
experiment
infect
cat
die
predict
prove
correct
natur
occur
fip
much
difficult
treat
experiment
diseas
must
stress
howev
trial
would
approv
without
inform
obtain
pharmacokinet
acut
chronic
toxic
efficaci
studi
conduct
laboratori
cat
first
attempt
use
target
antivir
drug
system
highli
fatal
diseas
veterinari
import
although
specif
antivir
drug
yet
avail
coronaviru
infect
peopl
anim
antivir
drug
viral
infect
peopl
hcv
develop
treatment
use
drug
provid
sound
base
applic
anim
diseas
fip
hcv
mainli
infect
liver
cell
caus
persist
viral
infect
major
peopl
howev
develop
liver
diseas
year
hcv
infect
clear
nonspecif
antivir
treatment
interferon
ribavirin
month
half
patient
recent
introduct
directact
antivir
drug
month
durat
consider
increas
cure
rate
hiv
infect
peopl
lead
prolong
asymptomat
state
eventu
advanc
hiv
diseas
infect
cell
macrophg
surviv
latent
state
antiretrovir
drug
use
combin
two
drug
success
use
reduc
viral
load
undetect
level
blood
hivaid
patient
howev
viru
rebound
discontinu
antivir
treatment
necessit
lifelong
antivir
treatment
dissemin
viru
brain
mainli
mediat
virusinfect
macrophag
subsequ
develop
neurolog
diseas
occur
hiv
infect
therefor
neurolog
impair
still
remain
import
problem
even
antivir
treatment
era
preced
antivir
treatment
hcv
infect
show
treatment
outcom
viral
clearanc
vs
viral
persist
treatment
durat
finit
vs
contin
presenc
neurolog
sequela
greatli
influenc
viral
pathogenesi
present
studi
limit
cat
fip
repres
spectrum
age
diseas
form
although
number
treat
cat
small
surpris
amount
inform
glean
long
treat
potenti
side
effect
identifi
clinic
form
fip
like
respond
therapi
potenti
indic
treatment
failur
success
field
studi
base
experi
gain
pharmacokinet
efficaci
studi
undertaken
laboratori
cat
initi
treatment
period
set
week
base
experiment
studi
ultim
extend
week
longer
base
experi
obtain
trial
progress
final
treatment
period
closer
month
use
treat
hcv
infect
peopl
directact
antivir
drug
difficulti
treat
neurolog
diseas
also
anticip
experiment
studi
side
effect
accept
includ
sting
upon
inject
dermal
subcutan
inflamm
much
drug
given
spot
also
seen
first
laboratori
cat
seriou
side
effect
seen
beforehand
laboratori
cat
limit
kitten
involv
retard
develop
adult
teeth
retent
delay
loss
decidu
teeth
treatment
success
induc
signific
remiss
diseas
sign
regress
lesion
cat
result
confirm
find
rapid
revers
clinic
sign
laboratori
cat
experiment
fip
treat
extend
knowledg
drug
effect
broad
spectrum
form
natur
occur
fip
cat
came
variou
part
usa
even
peru
thu
confirm
geograph
divers
field
strain
fipv
equal
suscept
inhibitor
mark
reduct
viral
rna
transcript
occur
effus
within
day
treatment
associ
rapid
improv
health
howev
diseas
remiss
sustain
month
longer
cat
failur
achiev
longterm
diseas
remiss
ultim
associ
occurr
neurolog
diseas
absenc
gross
abdomin
lesion
recurr
persist
gross
abdomin
lesion
presenc
histolog
lesion
brain
andor
eye
find
indic
fipv
greater
propens
spread
bodi
caviti
brain
previous
assum
especi
given
enough
time
spread
like
involv
infect
macrophag
enter
brain
small
blood
vessel
mening
ependyma
cat
develop
neurolog
diseas
either
treatment
week
treatment
stop
like
explan
delay
well
therapeut
benefit
higher
dosag
still
abl
penetr
brain
level
cerebrospin
fluid
plasma
brain
h
subcutan
inject
dosag
mgkg
unpublish
data
although
rel
brain
drug
concentr
cat
low
still
higher
level
requir
inhibit
viru
replic
tissu
cultur
given
find
assum
higher
dosag
would
allow
drug
brain
assumpt
bolster
experi
two
cat
manifest
neurolog
sign
increas
dosag
mgkg
one
cat
result
notic
improv
elimin
sign
brain
diseas
extend
treatment
period
almost
month
dosag
mgkg
appear
delay
progress
neurolog
sign
second
cat
wherea
attempt
reduc
total
daili
dosag
cat
mgkg
mgkg
caus
neurolog
sign
worsen
suggest
dosag
mgkg
allow
enough
cross
bloodbrain
barrier
retard
elimin
neurolog
sign
high
incid
central
nervou
system
cn
diseas
studi
greater
previous
report
unexpect
given
cat
sign
brain
spinal
cord
involv
exclud
trial
cn
diseas
much
like
occur
older
cat
dri
drytowet
diseas
young
cat
wet
fip
indic
fipv
enter
brain
mani
cat
given
enough
time
infect
cn
appear
involv
peritonealtyp
macrophag
fipvinfect
cell
brain
cat
neurolog
fip
close
resembl
periton
rather
resid
brain
macrophag
surpris
macrophag
migrat
variou
tissu
includ
brain
carri
immun
surveil
also
target
rang
infecti
agent
fipv
infect
macrophag
play
major
role
viral
dissemin
brain
patient
hiv
detect
viru
brain
occur
within
week
infect
howev
neurolog
impair
usual
occur
later
stage
antihiv
drug
also
reduc
frequenc
sever
neurolog
impair
observ
fipv
present
studi
also
altern
explan
possibl
extracn
involv
may
inhibit
develop
brain
diseas
vice
versa
common
see
cn
diseas
occur
absenc
viscer
diseas
vice
versa
suppress
viral
replic
nonneuron
tissu
may
also
enhanc
posit
select
mutant
neurotrop
neurovirul
howev
proof
latter
would
requir
consider
studi
use
laboratori
cat
certain
form
fip
appear
influenc
treatment
success
behavior
treatment
treat
ocular
fip
paradox
respond
extrem
well
even
though
ocular
lesion
respond
treatment
three
cat
eye
involv
ultim
succumb
brain
diseas
thu
support
close
anatom
relationship
eye
cn
chronic
ileocec
colon
involv
stunt
growth
older
cat
also
carri
bad
prognosi
studi
number
cat
appear
develop
abdomin
effus
termin
manifest
diseas
host
factor
also
associ
reduc
respons
antivir
treatment
viral
infect
hcv
includ
age
sex
liver
cirrhosi
fibrosi
race
bodi
weight
emerg
resist
major
concern
antivir
drug
fipv
rare
transmit
cat
cat
drug
resist
occur
would
problem
individu
treat
cat
entir
popul
although
viral
resist
observ
passag
vitro
suggest
resist
easili
acquir
longterm
repetit
treatment
vivo
may
stronger
select
factor
howev
viral
resist
appear
respons
relaps
abdomin
diseas
five
treat
cat
cat
granulomatouslik
mass
often
colon
ileocecalcol
lymph
node
may
provid
protect
place
virus
persist
protect
pathogen
within
granuloma
welldocu
phenomenon
mycobacteria
appli
pathogen
virus
statu
liver
diseas
cirrhosi
hcv
infect
also
increas
risk
relaps
necessit
longer
treatment
indic
virus
may
also
protect
drug
certain
protect
site
format
protect
granuloma
involv
larg
number
chemokin
cytokin
upregul
chemokin
receptor
addressin
selectin
integrin
persist
pathogen
protect
site
may
requir
higher
dose
drug
longer
treatment
period
treatment
failur
may
also
result
inabl
host
mount
protect
immun
respons
period
viru
replic
suppress
failur
observ
hcv
infect
peopl
tcellmedi
immun
play
import
role
protect
immun
occur
acut
infect
hcv
equal
greater
proport
fipv
infect
possibl
synerg
tcellmedi
viral
clearanc
antivir
drug
therapi
cat
fip
remain
investig
may
also
merit
combin
antivir
drug
stimul
tcell
immun
fip
treatment
combin
interferon
ribavirin
treatment
hcv
infect
sustain
remiss
cat
treat
week
longer
somewhat
predict
cat
month
age
present
acut
sign
either
abdomin
thorac
effus
fip
made
younger
three
cat
trial
close
resembl
laboratori
cat
acuteonset
effus
fip
respond
well
diseas
acut
may
allow
less
time
viru
spread
brain
eye
acut
diseas
may
also
allow
less
time
infect
perman
compromis
protect
immun
respons
seventh
cat
extrem
six
younger
cat
oldest
cat
studi
year
present
substanti
weight
loss
diseas
limit
mesenter
lymph
node
suffer
diseas
relaps
requir
reinstitut
treatment
relaps
ident
present
condit
involv
cn
cat
form
fip
known
undergo
spontan
remiss
indic
tip
point
immun
diseas
cat
demonstr
wisdom
reinstitut
treatment
relaps
occur
provid
relaps
involv
eye
nervou
system
still
drug
respons
determin
minim
period
treatment
base
progress
increas
treatment
time
base
favor
respons
treatment
expect
base
experiment
studi
week
treatment
might
suffici
henc
use
start
point
howev
studi
indic
minimum
treatment
period
closer
week
surprisingli
close
usual
week
period
requir
treat
human
hcv
use
proteas
inhibitor
howev
treatment
period
hcv
vari
week
differ
peopl
cat
outwardli
healthi
activ
grow
week
treatment
total
protein
white
blood
cell
count
still
return
normal
six
cat
nonetheless
decis
made
stop
treatment
week
long
period
outwardli
normal
health
whether
treat
longer
period
time
would
prevent
diseas
relaps
week
stop
treatment
open
conjectur
rais
point
long
treatment
requir
cat
also
rais
question
long
remiss
must
sustain
declar
diseas
cure
rather
sustain
remiss
longest
diseasefre
period
month
time
write
five
cat
free
infect
sign
month
base
clinic
histolog
evid
neurolog
diseas
time
fatal
relaps
would
seem
viru
eventu
reach
brain
may
import
limit
factor
antivir
drug
treatment
fip
although
onethird
cat
longterm
survivor
cat
trial
provid
basi
futur
studi
antivir
drug
follow
cat
treatabl
stop
effort
normal
health
return
almost
treat
cat
limit
studi
albeit
sever
week
month
import
recogn
univers
viral
pathogen
embrac
pioneer
drug
develop
clinic
appli
human
diseas
hivaid
hepat
c
middl
east
respiratori
syndrom
sever
acut
respiratori
viru
ebola
influenza
inhibit
fipv
effect
condit
studi
decreas
viru
replic
caus
remiss
diseas
sign
cat
natur
occur
fip
outsid
cn
howev
sustain
remiss
studi
apt
occur
kitten
week
age
present
acut
onset
wet
fip
cat
dri
fip
limit
mesenter
lymph
node
less
like
occur
cat
greater
week
age
present
dri
drytowet
ocular
diseas
failur
achiev
sustain
remiss
associ
either
high
incid
neurolog
diseas
treatment
stop
recurr
abdomin
lesion
antivir
treatment
seem
slow
progress
neurolog
diseas
revers
dosag
employ
trial
reason
recurr
extraneurolog
diseas
face
treatment
determin
associ
mutat
proteas
bind
region
